{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:29:19Z","timestamp":1787110159460,"version":"build-2736575974"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016321","name":"Lanzhou University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Gansu Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105481","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:19:50Z","timestamp":1783628390000},"page":"105481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging mechanisms and targetable pathways in immune checkpoint inhibitor\u2011associated thyroid dysfunction: From pathogenesis to potential intervention"],"prefix":"10.1016","volume":"225","author":[{"given":"Tianying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengtong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-5625","authenticated-orcid":false,"given":"Yong-xun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105481_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2174\/1381612829666230904150808","article-title":"Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases","volume":"29","author":"Akhter","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.critrevonc.2026.105481_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2026.105481_bib4","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105481_bib5","first-page":"1","article-title":"Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease","author":"Arawker","year":"2025","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.critrevonc.2026.105481_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","article-title":"Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial","volume":"15","author":"Ascierto","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105481_bib7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s12020-025-04447-w","article-title":"Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study","volume":"90","author":"Bai","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2026.105481_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1690196","article-title":"Pre-existing subclinical hypothyroidism and low free thyroxine in patients undergoing immune checkpoint inhibitor therapies is a risk factor for overt hypothyroidism","volume":"16","author":"Bai","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib9","first-page":"174","article-title":"Gastrointestinal disorders as immune-related adverse events","volume":"2","author":"Balducci","year":"2021","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"10.1016\/j.critrevonc.2026.105481_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110530","article-title":"Role of the CXCR6\/CXCL16 axis in autoimmune diseases","volume":"121","author":"Bao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Calabr\u00f2","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf122","article-title":"The Risk of Adrenal Insufficiency after Treatment with Relatlimab in Combination with Nivolumab is Higher than Expected","author":"Chamorro-Pareja","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.critrevonc.2026.105481_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib19","first-page":"145","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm. Metab. Res. Horm. Stoffwechs. Horm. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib20","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib21","article-title":"The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?","volume":"198","author":"Di Giacomo","year":"2024","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"10.1016\/j.critrevonc.2026.105481_bib22","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105481_bib23","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101773","article-title":"Chemokines in thyroid autoimmunity","volume":"37","author":"Ferrari","year":"2023","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-025-01026-w","article-title":"Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention","volume":"22","author":"Gao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib26","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0064","article-title":"Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes","volume":"31","author":"Garc\u00eda-Go\u00f1i","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105481_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","article-title":"Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution","volume":"41","author":"Guaraldi","year":"2018","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.critrevonc.2026.105481_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-025-02608-2","article-title":"Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes","author":"Hammerstad","year":"2025","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.critrevonc.2026.105481_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib31","doi-asserted-by":"crossref","first-page":"A802","DOI":"10.1210\/jendso\/bvac150.1660","article-title":"OR19-5 Dissecting Thyroidal Pathways Activated by PD-L1 Blockade Identifies New Mechanisms for Thyroiditis Triggered by Immune Checkpoint Inhibitors","volume":"6","author":"Hou","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1470-2045(25)00401-2","article-title":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Hsu","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152370","article-title":"CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies","volume":"52","author":"Hsu","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1325575","article-title":"Th17\/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target","volume":"14","author":"Huo","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib35","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr. J."},{"key":"10.1016\/j.critrevonc.2026.105481_bib37","doi-asserted-by":"crossref","unstructured":"Investigating Likelihood and Time to Recovery of Thyroiditis and Hypophysitis Following Immune Checkpoint Inhibitor Therapy, 2025. Endocr. Pract., AACE Annual Meeting 2025 Abstracts - Part 2 31, S16\u2013S17. https:\/\/doi.org\/10.1016\/j.eprac.2025.09.054.","DOI":"10.1016\/j.eprac.2025.09.054"},{"key":"10.1016\/j.critrevonc.2026.105481_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1221723","article-title":"Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects","volume":"14","author":"Iwamoto","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-Related Thyroiditis with Immune Checkpoint Inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib42","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007785","article-title":"XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer","volume":"11","author":"Jenkins","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2026.105481_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3949\/ccjm.90a.22032","article-title":"Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management","volume":"90","author":"Kennedy","year":"2023","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib47","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib50","article-title":"Targeted immunotherapies for Graves\u2019 thyroidal & orbital diseases","volume":"16","author":"Lee","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000508789","article-title":"Novel Approaches for Immunosuppression in Graves\u2019 Hyperthyroidism and Associated Orbitopathy","volume":"9","author":"Lee","year":"2020","journal-title":"Eur. Thyroid. J."},{"key":"10.1016\/j.critrevonc.2026.105481_bib52","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105481_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1169173","article-title":"Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib54","article-title":"The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2024.2433628","article-title":"N6-methyladenosine modification of THBS1 induced by affluent WTAP promotes Graves\u2019 ophthalmopathy progression through glycolysis to affect Th17\/Treg balance","volume":"58","author":"Li","year":"2025","journal-title":"Autoimmunity"},{"key":"10.1016\/j.critrevonc.2026.105481_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104163","article-title":"Gut microbiome in modulating immune checkpoint inhibitors","volume":"82","author":"Li","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105481_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41467-021-21241-0","article-title":"Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105481_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8251","article-title":"DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity","volume":"10","author":"Li","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108307","article-title":"An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade","volume":"101","author":"Liu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24701","article-title":"High levels of thyroid hormones promote recurrence of Graves\u2019 disease via overexpression of B-cell-activating factor","volume":"36","author":"Liu","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.critrevonc.2026.105481_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-023-01768-0","article-title":"Epigenetic reprogramming of Runx3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib62","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1553","article-title":"Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma","volume":"14","author":"Luo","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.859013","article-title":"Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/imr.13427","article-title":"Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105481_bib67","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2026.105481_bib68","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib69","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2024.08.029","article-title":"Systemic T-cell activation and IFN-\u03b3 activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-\u03b3-directed therapies","volume":"155","author":"Nguyen","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib72","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib73","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.critrevonc.2026.105481_bib74","first-page":"1","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a network meta-analysis of the current evidence","volume":"3","author":"Ouyang","year":"2024","journal-title":"Acta Mater. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves\u2019 Hyperthyroidism: A Phase I Study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib77","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.3390\/ijms241310526","article-title":"RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies","volume":"24","author":"Pollack","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105481_bib78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib79","article-title":"The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1\/PD-L1 pathway","volume":"212","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2020","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.critrevonc.2026.105481_bib80","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105481_bib81","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1038\/s41467-024-50007-7","article-title":"Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease","volume":"15","author":"Saevarsdottir","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105481_bib82","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/1750743X.2024.2353539","article-title":"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event","volume":"16","author":"Sasaki","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2026.105481_bib84","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2023.03.014","article-title":"Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial","volume":"187","author":"Schadendorf","year":"2023","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2026.105481_bib85","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers14030682","article-title":"Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial","volume":"14","author":"Schwarze","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105481_bib86","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0138","article-title":"Reversibility of immune checkpoint inhibitor-induced hypothyroidism","volume":"32","author":"Seo","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110757","article-title":"IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment","volume":"123","author":"Song","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib89","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1042\/CS20200475","article-title":"Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis","volume":"134","author":"Su","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.critrevonc.2026.105481_bib90","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib91","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1097\/MJT.0000000000001680","article-title":"Nivolumab\/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma","volume":"30","author":"Thomas","year":"2023","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.critrevonc.2026.105481_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667650","article-title":"The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1\/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis","volume":"11","author":"Tian","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2023.0542","article-title":"The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function","volume":"34","author":"Tsai","year":"2024","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105481_bib94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib95","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/genes16121506","article-title":"Insights into the Genetic and Epigenetic Landscape of Endocrine Autoimmunity: A Systematic Review","volume":"16","author":"Tuli","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105481_bib96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12020-025-04164-4","article-title":"Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction","volume":"88","author":"Wang","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2026.105481_bib97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ol.2024.14700","article-title":"PI3K\/AKT\/mTOR and PD\u20111\/CTLA\u20114\/CD28 pathways as key targets of cancer immunotherapy (Review)","volume":"28","author":"Wang","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105481_bib98","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1186\/s12885-025-14097-w","article-title":"Thyroid dysfunction as a predictor of PD- 1\/PD-L1 inhibitor efficacy in advanced lung cancer","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2430066","article-title":"The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma","volume":"14","author":"Wiecken","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105481_bib101","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction","volume":"108","author":"Wright","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib102","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.3390\/ijms25136883","article-title":"The Role of the Immune System in the Course of Hashimoto\u2019s Thyroiditis: The Current State of Knowledge","volume":"25","author":"Wro\u0144ska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105481_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110452","article-title":"Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury","volume":"121","author":"Wu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib104","first-page":"148","article-title":"A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME","volume":"44","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.critrevonc.2026.105481_bib105","article-title":"Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113024","article-title":"Integrative multi-omics characterization of 12 syngeneic mouse models","volume":"28","author":"Xu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105481_bib107","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0328","article-title":"Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors","volume":"14","author":"Yamauchi","year":"2025","journal-title":"Eur. Thyroid. J."},{"key":"10.1016\/j.critrevonc.2026.105481_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115555","article-title":"Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors","volume":"166","author":"Yan","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib109","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jcph.1804","article-title":"Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review","volume":"61","author":"Yang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib110","first-page":"4229","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib112","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","article-title":"Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction","volume":"108","author":"Zhang","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib113","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s10637-020-00952-z","article-title":"Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics","volume":"38","author":"Zhang","year":"2020","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105481_bib114","article-title":"Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib116","article-title":"Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib117","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5603\/ep.102030","article-title":"Gut-thyroid axis: investigating the causality between the gut microbiota and autoimmune thyroid disease based on a Mendelian randomization study","volume":"76","author":"Zheng","year":"2025","journal-title":"Endokrynol. Pol."},{"key":"10.1016\/j.critrevonc.2026.105481_bib118","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105481_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105481_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103719","article-title":"FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases","volume":"24","author":"Zhu","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.critrevonc.2026.105481_bib121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10238-024-01304-4","article-title":"Intestinal microbiota regulates the gut-thyroid axis: the new dawn of improving Hashimoto thyroiditis","volume":"24","author":"Zhu","year":"2024","journal-title":"Clin. Exp. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:57:31Z","timestamp":1787108251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":121,"alternative-id":["S1040842826003689"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105481","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging mechanisms and targetable pathways in immune checkpoint inhibitor\u2011associated thyroid dysfunction: From pathogenesis to potential intervention","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105481"}}